News

Shattuck Labs Reveals Financial Progress Amid Drug Trials

Shattuck Labs Reveals Financial Progress Amid Drug Trials

Shattuck Labs Financial Results Summary

Shattuck Labs, Inc. (STTK), a biotechnology company dedicated to pioneering innovative therapies for inflammatory and immune-mediated diseases, has put forth robust financial results for their latest quarter. Their comprehensive efforts toward the development of novel therapeutics targeting TNF superfamily receptors signify a pivotal advancement in their business strategy and contribute positively to their financial standing.

IND Application and Clinical Trials

Recently, Shattuck Labs submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to evaluate SL-325 in a Phase 1 clinical trial involving healthy participants. The company anticipates receiving clearance for this application in the upcoming quarter. The commencement of trial dosing is planned for Q3 2025, displaying their commitment to advancing critical research in the biotech field.

Clinical Trial Objectives

The Phase 1 clinical trial will primarily focus on assessing the safety, tolerability, immunogenicity, and pharmacokinetics of SL-325. Additionally, the trial aims to determine the recommended Phase 2 dose and dosing schedule for this promising candidate. Subject to regulatory approval, dosing for the first participant in the single ascending dose (SAD) portion is expected to begin soon, with plans to finalize this portion by Q2 2026.

Financial Highlights

As of the end of Q2 2025, Shattuck Labs reported a significant cash balance of approximately $50.5 million. This financial resilience is bolstered by the recent success of their private placement effort, with an anticipated total of about $103 million, after accounting for offering expenses. This funding is envisioned to support their operational needs well into 2029, providing a substantial runway for further development and clinical trials.

Quarterly Financial Overview

The financial results for the quarter highlight substantial research and development investments amounting to $8.7 million, a noticeable decrease compared to the previous year, demonstrating Shattuck's strategic efficiency. General and administrative expenses also witnessed a decrease, coming in at $4.4 million. Despite a net loss of $12.5 million, improvements were noted in comparison to the net loss of $21.6 million recorded in the same quarter the previous year.

Strategic Developments in 2025

Shattuck Labs continues to enrich its portfolio through the development of multiple preclinical DR3-based bispecific antibodies aimed at treating inflammatory bowel disease (IBD) alongside other autoimmune conditions. The nomination of a lead bispecific candidate from their preclinical pipeline is projected for 2025, marking another exciting chapter in their therapeutic development journey.

Participation in Healthcare Conferences

Shattuck Labs has actively engaged in key industry conferences, enhancing visibility for its advancements. CEO Taylor Schreiber delivered presentations at events including the 24th Annual Needham Virtual Healthcare Conference and the Leerink Partners Therapeutics Forum. These platforms enable Shattuck to share insights on their research progress and corporate strategy.

Future Path and Expectations

Looking ahead, Shattuck Labs is poised for a significant presence at the H.C. Wainwright 27th Annual Global Investment Conference. This event will feature a corporate presentation from leadership and opportunities for one-on-one discussions with investors. Shattuck’s road ahead appears optimistic as they gear up for additional Phase 2 clinical trials and continued exploration of funding avenues.

About Shattuck Labs, Inc.

Founded with a commitment to innovate, Shattuck Labs, Inc. specializes in developing first-in-class therapies for patients suffering from inflammatory and immune-mediated diseases. Their continued focus on pioneering drug development is evident in programs such as SL-325, a promising DR3 antagonist antibody targeting established therapeutic pathways. With bases in both Austin and Durham, Shattuck Labs is at the forefront of biotech innovation, aiming to significantly impact patient care in the coming years.

Frequently Asked Questions

What is SL-325?

SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to treat various inflammatory and immune-mediated diseases.

What is the current cash balance of Shattuck Labs?

As of the end of Q2 2025, Shattuck Labs reported a cash balance of approximately $50.5 million.

When is the Phase 1 clinical trial for SL-325 expected to start?

The dosing for the first participant in the Phase 1 clinical trial is anticipated to begin in Q3 2025.

How much funding is expected from the recent private placement?

Shattuck Labs expects to receive about $103 million from their recent oversubscribed private placement, which will support their operations into 2029.

What are the upcoming conferences Shattuck Labs will participate in?

Shattuck Labs plans to attend the H.C. Wainwright 27th Annual Global Investment Conference, where their CEO will present corporate updates and engage in one-on-one meetings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 30

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 93

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 74

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
PepsiCo Locks In Hyatt's 700-Property U.S. Supply Deal

Updated Category News Views 40

A hotel minibar is a lousy place to hunt for glamour, but it is a terrific place to spot durable distribution. PepsiCo has renewed its U.S. food and beverage relationship with Hyatt for 10 years, covering more than 700 properties. Nobody should pretend a hotel contract transforms a company with nearly $94 billion in 2025 revenue. Still, this is the sort of unflashy...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 25

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 52

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 81

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Health Monitor Network Strengthens Leadership in Data Insights

Updated Category News Views 195

Strategic Appointment in Health Monitor Network Health Monitor Network, a renowned leader in point of care marketing, has taken a significant leap towards enriching its data analytics and research capabilities with the appointment of Lucia Burchell as Senior Vice President, Analytics, Research & Insights. Burchell's role is poised to empower clients by providing profound...

Continue Reading
Empowering Smallholders in Palm Oil for Sustainable Growth

Updated Category News Views 192

Empowering Smallholders in Palm Oil for Sustainable Growth From financing smallholders to regenerating ecosystems and innovating supply chains, the Roundtable on Sustainable Palm Oil (RSPO) has gathered global stakeholders to explore scalable solutions. This annual conference, an important event in the palm oil industry's agenda, aims to accelerate the industry's...

Continue Reading
t'order Welcomes New CTO to Drive Global Expansion Efforts

Updated Category News Views 169

t'order Inc. Appoints New Chief Technology Officer t'order Inc. has made a significant move by appointing Theo Eom as its Chief Technology Officer. With his extensive background in the tech industry, Theo is expected to lead the company in its ambitious plans for growth and innovation in the table-ordering service sector. The Technology Experience of Theo Eom Theo Eom...

Continue Reading
Manasquan Bank Introduces Home Loans for Local Heroes

Updated Category News Views 266

Supporting Our Local Heroes with New Home Lending Programs Manasquan Bank has proudly introduced innovative home lending products specifically designed for the heroes in our community. This initiative encompasses the dedication provided by educators, first responders, and military personnel. Aimed at making homeownership more achievable, these programs illustrate the...

Continue Reading
Netflix's Strategic Moves Drive Subscriber Gains Amid Prices Rise

Updated Category News Views 285

Netflix's Surging Subscriber Growth Through New Releases Netflix Inc. (NASDAQ: NFLX) has seen a notable uptick in its stock as it capitalizes on substantial gains from international markets and successful content releases. Major titles like Squid Game Season 3 and Stranger Things Season 5 have been pivotal in attracting new subscribers and enhancing user engagement....

Continue Reading